Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective raised by analysts at Wells Fargo & Company from $745.00 to $800.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price suggests a potential upside of 5.38% from the stock’s current price.

Several other equities analysts have also issued reports on the company. Cantor Fitzgerald upped their target price on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Hsbc Global Res raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research note on Monday. Royal Bank Of Canada lifted their target price on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 29th. Finally, HSBC initiated coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They issued a “buy” rating and a $255.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $790.64.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $759.18 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.77 and a quick ratio of 4.22. The firm has a 50-day moving average of $757.70 and a 200-day moving average of $654.25. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $821.11. The company has a market cap of $79.79 billion, a P/E ratio of 18.27, a P/E/G ratio of 1.95 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping the consensus estimate of $10.74 by $0.70. The business had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the previous year, the company earned $12.07 earnings per share. Equities research analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 46.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. The trade was a 9.24% decrease in their position. The SEC filing for this sale provides additional information. 7.02% of the stock is currently owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in REGN. WPG Advisers LLC grew its holdings in Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 25 shares in the last quarter. Salomon & Ludwin LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $31,000. Board of the Pension Protection Fund purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $31,000. Finally, Caitlin John LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $34,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: JPMorgan raised its price target to $950 and kept an “overweight” rating — a sizable increase that signals strong analyst conviction and adds meaningful upside to the stock. Benzinga
• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and lifted its target to $865, reflecting continued confidence after Regeneron’s Q4 beat. Benzinga
• Positive Sentiment: Cantor Fitzgerald raised its target to $800 and maintained an “overweight” view, another vote of confidence supporting the rally. Benzinga
• Positive Sentiment: Wells Fargo lifted its price target to $800 (equal weight) — a modest boost that still reinforces momentum from the quarter. Benzinga
• Positive Sentiment: Regeneron highlighted new EYLEA HD presentations (QUASAR and ELARA results) at Angiogenesis 2026 — positive clinical data that can support the ophthalmology franchise outlook. EYLEA HD Presentations
• Positive Sentiment: Coverage roundup notes analysts revising forecasts after Regeneron’s upbeat Q4 results—consensus attention on the beat is lifting sentiment. Analyst Revisions After Q4
• Neutral Sentiment: Morgan Stanley nudged its target to $769 but kept an “equal weight” rating — a very small adjustment that signals limited near‑term upside from their view. TickerReport
• Neutral Sentiment: Market commentary pieces discuss Regeneron’s pipeline progress and valuation gap; useful context for longer‑term investors but not an immediate catalyst. Yahoo Finance
• Negative Sentiment: Truist trimmed its target slightly to $818 (still a “buy”) — a small downward tweak that may temper upside expectations from some investors. Benzinga

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.